CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor
Accession: CHEBI:76741
browse the term
Definition: An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on hydrogen as donors (EC 1.14.*.*).
Synonyms: related_synonym: EC 1.14.* inhibitor; EC 1.14.* inhibitors; inhibitor of oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*); inhibitor of oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*); inhibitors of oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*); inhibitors of oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*); oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitors; oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen inhibitor; oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen inhibitors
G
PTGS1
prostaglandin-endoperoxide synthase 1
decreases activity
EXP
Aspirin results in decreased activity of PTGS1 protein alternative form
CTD
PMID:12242329
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
G
PTGS1
prostaglandin-endoperoxide synthase 1
decreases activity
EXP
Antipyrine results in decreased activity of PTGS1 protein alternative form
CTD
PMID:12242329
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
G
PTGS2
prostaglandin-endoperoxide synthase 2
decreases expression
EXP
carprofen results in decreased expression of PTGS2 mRNA
CTD
PMID:15198222
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
G
SLC22A2
solute carrier family 22 member 2
decreases activity
EXP
Cimetidine results in decreased activity of SLC22A2 protein
CTD
PMID:36669674
NCBI chr 1:49,327,621...49,348,435
Ensembl chr 1:49,327,296...49,348,435
G
CYP2C41
cytochrome P450 2C41
affects metabolic processing increases hydroxylation
EXP
CYP2C9 protein affects the metabolism of Diclofenac CYP2C19 protein results in increased hydroxylation of Diclofenac
CTD
PMID:15677349 PMID:15801540
G
PTGS1
prostaglandin-endoperoxide synthase 1
decreases activity
EXP
Diclofenac results in decreased activity of PTGS1 protein alternative form
CTD
PMID:12242329
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
G
PTGS2
prostaglandin-endoperoxide synthase 2
decreases expression
EXP
Etodolac results in decreased expression of PTGS2 mRNA
CTD
PMID:15198222
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
G
CPNE6
copine 6
decreases activity
EXP
Flufenamic Acid results in decreased activity of DHRS4 protein
CTD
PMID:17827741
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
G
SLC47A1
solute carrier family 47 member 1
decreases activity
EXP
hexaconazole results in decreased activity of SLC47A1 protein
CTD
PMID:36669674
NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
G
SLC47A2
solute carrier family 47 member 2
decreases activity
EXP
hexaconazole results in decreased activity of SLC47A2 protein
CTD
PMID:36669674
NCBI chr 5:40,491,306...40,515,430
Ensembl chr 5:40,491,933...40,540,136
G
PTGS1
prostaglandin-endoperoxide synthase 1
decreases activity
EXP
Ibuprofen results in decreased activity of PTGS1 protein alternative form
CTD
PMID:12242329
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
G
PTGS2
prostaglandin-endoperoxide synthase 2
increases expression
EXP
Ibuprofen results in increased expression of PTGS2 protein
CTD
PMID:16105799
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
G
HEXB
hexosaminidase subunit beta
multiple interactions
EXP
Indomethacin promotes the reaction [mastoparan results in increased secretion of HEXB protein]
CTD
PMID:21671308
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
G
PTGS1
prostaglandin-endoperoxide synthase 1
decreases activity
EXP
Indomethacin results in decreased activity of PTGS1 protein alternative form
CTD
PMID:12242329
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
G
PTGS1
prostaglandin-endoperoxide synthase 1
decreases activity
EXP
Dipyrone results in decreased activity of PTGS1 protein alternative form
CTD
PMID:12242329
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
G
IL1B
interleukin 1 beta
decreases expression
EXP
nimesulide results in decreased expression of IL1B mRNA
CTD
PMID:19638440
NCBI chr17:37,019,329...37,033,388
Ensembl chr17:37,019,329...37,024,458
G
PTGS2
prostaglandin-endoperoxide synthase 2
decreases expression
EXP
nimesulide results in decreased expression of PTGS2 mRNA
CTD
PMID:15198222
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
G
PTGS2
prostaglandin-endoperoxide synthase 2
decreases expression
EXP
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PTGS2 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PTGS2 protein
CTD
PMID:12857884 PMID:15198222
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
G
RELA
RELA proto-oncogene, NF-kB subunit
decreases localization
EXP
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased localization of RELA protein
CTD
PMID:12857884
NCBI chr18:51,550,003...51,558,861
Ensembl chr18:51,550,040...51,558,875
G
NR1I2
nuclear receptor subfamily 1 group I member 2
increases activity
EXP
Omeprazole results in increased activity of NR1I2 protein
CTD
PMID:27732639
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
G
SLC22A6
solute carrier family 22 member 6
multiple interactions
EXP
[Omeprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican
CTD
PMID:36243147
NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
G
PTGS1
prostaglandin-endoperoxide synthase 1
decreases activity
EXP
Acetaminophen results in decreased activity of PTGS1 protein alternative form
CTD
PMID:12242329
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
G
UGT1A6
UDP glucuronosyltransferase 1 family, polypeptide A6
increases glucuronidation
EXP
UGT1A6 protein results in increased glucuronidation of Acetaminophen
CTD
PMID:11903872
NCBI chr25:45,081,655...45,161,584
Ensembl chr25:45,032,130...45,160,941
G
SLC22A2
solute carrier family 22 member 2
decreases activity
EXP
penconazole results in decreased activity of SLC22A2 protein
CTD
PMID:36669674
NCBI chr 1:49,327,621...49,348,435
Ensembl chr 1:49,327,296...49,348,435
G
SLC22A5
solute carrier family 22 member 5
decreases activity
EXP
penconazole results in decreased activity of SLC22A5 protein
CTD
PMID:36669674
NCBI chr11:20,659,023...20,686,359
Ensembl chr11:20,598,888...20,683,087
G
SLC47A1
solute carrier family 47 member 1
decreases activity
EXP
penconazole results in decreased activity of SLC47A1 protein
CTD
PMID:36669674
NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
G
SLC47A2
solute carrier family 47 member 2
decreases activity
EXP
penconazole results in decreased activity of SLC47A2 protein
CTD
PMID:36669674
NCBI chr 5:40,491,306...40,515,430
Ensembl chr 5:40,491,933...40,540,136
G
CYP1A2
cytochrome P450 family 1 subfamily A member 2
affects metabolic processing
EXP
CYP1A2 protein affects the metabolism of Phenacetin
CTD
PMID:15801540
NCBI chr30:37,818,400...37,824,192
Ensembl chr30:37,799,140...37,824,135
G
PTGS1
prostaglandin-endoperoxide synthase 1
decreases activity
EXP
Phenacetin results in decreased activity of PTGS1 protein alternative form
CTD
PMID:12242329
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
G
AHR
aryl hydrocarbon receptor
multiple interactions
EXP
[2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz; [prochloraz binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein; [salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz
CTD
PMID:24389113
NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444
G
CYP1A1
cytochrome P450 family 1 subfamily A member 1
multiple interactions
EXP
[prochloraz binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein
CTD
PMID:24389113
NCBI chr30:37,793,277...37,799,535
Ensembl chr30:37,793,508...37,796,866
G
PTGS2
prostaglandin-endoperoxide synthase 2
decreases expression
EXP
Sulindac results in decreased expression of PTGS2 protein
CTD
PMID:12857884
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
G
RELA
RELA proto-oncogene, NF-kB subunit
decreases localization
EXP
Sulindac results in decreased localization of RELA protein
CTD
PMID:12857884
NCBI chr18:51,550,003...51,558,861
Ensembl chr18:51,550,040...51,558,875
G
SLC22A2
solute carrier family 22 member 2
decreases activity
EXP
tebuconazole results in decreased activity of SLC22A2 protein
CTD
PMID:36669674
NCBI chr 1:49,327,621...49,348,435
Ensembl chr 1:49,327,296...49,348,435
G
SLC22A5
solute carrier family 22 member 5
decreases activity
EXP
tebuconazole results in decreased activity of SLC22A5 protein
CTD
PMID:36669674
NCBI chr11:20,659,023...20,686,359
Ensembl chr11:20,598,888...20,683,087
G
SLC47A1
solute carrier family 47 member 1
decreases activity
EXP
tebuconazole results in decreased activity of SLC47A1 protein
CTD
PMID:36669674
NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
G
SLC47A2
solute carrier family 47 member 2
decreases activity
EXP
tebuconazole results in decreased activity of SLC47A2 protein
CTD
PMID:36669674
NCBI chr 5:40,491,306...40,515,430
Ensembl chr 5:40,491,933...40,540,136
G
PTGS2
prostaglandin-endoperoxide synthase 2
decreases expression
EXP
tolfenamic acid results in decreased expression of PTGS2 mRNA
CTD
PMID:15198222
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
G
SLC22A5
solute carrier family 22 member 5
decreases activity
EXP
triticonazole results in decreased activity of SLC22A5 protein
CTD
PMID:36669674
NCBI chr11:20,659,023...20,686,359
Ensembl chr11:20,598,888...20,683,087
G
SLC47A1
solute carrier family 47 member 1
decreases activity
EXP
triticonazole results in decreased activity of SLC47A1 protein
CTD
PMID:36669674
NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
G
NR1I2
nuclear receptor subfamily 1 group I member 2
increases activity
EXP
Troleandomycin results in increased activity of NR1I2 protein
CTD
PMID:27732639
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
G
SLC22A5
solute carrier family 22 member 5
decreases activity
EXP
uniconazole results in decreased activity of SLC22A5 protein
CTD
PMID:36669674
NCBI chr11:20,659,023...20,686,359
Ensembl chr11:20,598,888...20,683,087
G
SLC47A1
solute carrier family 47 member 1
decreases activity
EXP
uniconazole results in decreased activity of SLC47A1 protein
CTD
PMID:36669674
NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all
Path 1
CHEBI ontology
409
role
409
biological role
409
biochemical role
369
enzyme inhibitor
280
EC 1.* (oxidoreductase) inhibitor
34
EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor
17
EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor +
0
EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor +
7
EC 1.14.13.78 (ent-kaurene oxidase) inhibitor +
2
EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor +
3
EC 1.14.15.* (oxidoreductase acting on paired donors, with reduced Fe-S protein as one donor, incorporating 1 O atom) inhibitor +
0
EC 1.14.16.* (oxidoreductase acting on paired donors, reduced pteridine as one donor, incorporating 1 atom of oxygen) inhibitor +
0
EC 1.14.17.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen and with reduced ascorbate as one donor, and incorporation of one atom of oxygen) inhibitor +
0
EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitor +
0
EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor +
9